¶µ¼ø

Èø¿¬¡¡ÇîÌé

¶µ¼ø¼Ì¿¿

ÀÄÌÚ¡¡³Ø
Æ⻳¡¡âù¬
äÌî¡¡Áï
Ë­ÅÄ¡¡·½»Ò

½Ú¶µ¼ø

º´µ×´Ö¡¡µü
¾®ÎÓ¡¡²íÉ×
ºÇ¾å¡¡Âó»ù
Àî¾å¡¡¹ä
¾¾Åç¡¡Íý»Î

½õ¶µ

»°³Ñ¡¡Ìмù
µÈ×¢¡¡¾¼»Ò
ÊƱʡ¡·òÆÁ
éÃÅÄ¡¡¹À°ì
À¶¿å ´«°ìϯ
Ãݱʡ¡¿¸²ð
ÅìÛê¡¡¿µ¼¡Ïº
²®ÌŸ¹­
ÎëÌÚ¡¡·°
ÂçÌÚ¡¡°ì¹ä
½¡Áü¡¡¹À»Ê
»³Æâ¡¡±Ñ¿Ã
ÂçÆâ¡¡¸üÂÀϺ
ÁÒÅÄ¡¡Ä¾¼ù
ÅϲÅÉß¡¡Í£»Ê
¼íÌî¡¡Ëã¼Â
À¶¿å¡¡Å¯Ìé
Ê¡ÅÄ¡¡Âçµ­
²Å»³¡¡ÎèÆà
ÅÏÊÕ¡¡·û
Ê¡ÅÄ¡¡·ò»Ö
Æ£°æ¡¡É´¹ç»Ò
ÇϾ졡μ
㻡¡½á
ÌÚÅè¡¡ÎÉÏÂ
Æ»ËÜ¡¡¸²µÈ
¿¹Àî¡¡ÏÂɧ
Êõ´Ø¡¡ÌÀ»Ò
°ËÆ£¡¡Íµ¹¯
±Ý¡¡·¼ÂÀϺ
¸ÞÌ£¡¡Âó
ÅÏî´¡¡µ®»Ë
»³ÅÄ¡¡ÀéæÆ
Ä顡ͳ´õ
ÂçÌÚ¡¡ÍÎÊ¿
·ªÎÓ¡¡±Ñ¿Í
¿¹Àî¡¡ÊË»Ò
Âç±É¡¡è½²Â
ÇòÀС¡¤á¤°¤ß
»û»³¡¡Í§Èþ
Èõ¸ý¡¡ÍÛÂç
Ì«¡¡¶³Êå
ÌÚº´ÌÚ¡¡½ÓÊå
ÎëÌÚ¡¡Î´Ç·
ĹëÀî¡¡Ì÷¹¸
ÀÖÈø¡¡Î¼
Æ£²¬¡¡Â繸
·¦Á°¡¡º»·Ã»Ò
µÈËÜ¡¡¾ºÊ¿
¾®¾ë¸¶¡¡±Í

¤½¤Î¾

¡Ê¥ì¥¸¥Ç¥ó¥È¡Ë

ÎëÌÚ¡¡Âç²Ï
Æ£¿¹¡¡ºÌ»Ò
µÈ¾¾¡¡ô¥
ÃÓÅÄ¡¡»ç
Æ⸶¡¡¸øÇ·
ÁðÅÄ¡¡½Ù
²¼Ìî¡¡Ëü·ë»Ò
ÎëÌÚ¡¡Í§Ìé
´Üƶ¡¡¿µÇ·²ð
ÁáÀͺµ®
²ÃÆ£¡¡¤æ¤¤¤«
º´Ìî¡¡¾´²µ
ÅÄùõ¡¡æÆÂÀ
ÃæΤ¡¡Íý¿Í
Ìî¸ý¡¡ÀµÀ²
»³Ã桡ͺÂÀ

¹ÖºÂ¡Ê¸¦µæ¼¼¡Ë¤Î³µÍ×
¡¡¾¼ÏÂ7ǯ12·î¡¢Èõ¸ý½õ¹°¤¬ÊªÎųضµ¼¼¤Î½éÂ嶵¼ø¤Ë°Ñ¾ü¤µ¤ì¤¿¤³¤È¤ò¤â¤Ã¤Æ¡¢Åö¹ÖºÂ¤Î³«ÀߤȤ·¤Æ¤ª¤ê¤Þ¤¹¡£¾¼ÏÂ24ǯ5·î¡¢ÆüËÜ°å³ØÊü¼ÍÀþ³Ø²ñ·èµÄ¤Ë´ð¤Å¤­¡¢»ü·Ã°åÂç¤Ë¤ª¤¤¤Æ¤â¶µ¼¼Ì¾¤òÊü¼ÍÀþ°å³Ø¶µ¼¼¤Ë²þ̾¤·¤Þ¤·¤¿¡£¾¼ÏÂ35ǯ12·î¤ËÃ渶°ì¿Ã¤¬Âè2Â嶵¼ø¡¢¾¼ÏÂ48ǯ9·î¤Ë˾·î¹¬Éפ¬Âè3Â嶵¼ø¡¢Ê¿À®7ǯ4·î¤ËÀî¾å·û»Ê¤¬Âè4Â嶵¼ø¡¢Ê¿À®10ǯ1·î¤ËÊ¡ÅĹñɧ¤¬Âè5Â嶵¼ø¡¢Ê¿À®29ǯ4·î¤ËÈø¿¬ÇîÌ餬Âè6Â嶵¼ø¤Ë½¢Ç¤¤·¸½ºß¤Ë»ê¤ê¤Þ¤¹¡£
°å³Ø²Ê¶µ°é¤Ë¤Ä¤¤¤Æ
¡¡Êü¼ÍÀþ°å³Ø¤Î´ðÁ䫤éÎ×¾²±þÍѤޤǤò¡¢°å³Ø²Ê3ǯÀ¸¤«¤é6ǯÀ¸¤òÂоݤ˶µ°é¤ò¹Ô¤Ã¤Æ¤¤¤Þ¤¹¡£Êü¼ÍÀþ°å³Ø¤Î´ðÁäǤϡ¢²èÁü¿ÇÃǤθ¶Íý¡¢Êü¼ÍÀþÀ¸Êª³Ø¡¢Êü¼ÍÀþ¼£ÎųØÁíÏÀ¤Î¹ÖµÁ¤ò¹Ô¤¤¤Þ¤¹¡£Î×¾²°å³Ø¼ðáç³Ø¤Ç¤ÏÊü¼ÍÀþ³ÆÏÀ¡¢Î×¾²°å³Ø²èÁü¿ÇÃdzؤǤϲèÁü¿ÇÃdzÆÏÀ¡Ê³Ë°å³Ø¿ÇÃǤÈĶ²»ÇÈ¿ÇÃǤò´Þ¤à¡Ë¤È¥¤¥ó¥¿¡¼¥Ù¥ó¥·¥ç¥Ê¥ë¥é¥¸¥ª¥í¡¼(IVR)¤Î¹ÖµÁ¤ò¹Ô¤¤¤Þ¤¹¡£Á´²ÊÎ×¾²¼Â½¬¤È¿ÇÎÅ»²²Ã·¿Î×¾²¼Â½¬¤Ç¤Ï¡¢²èÁü¿ÇÃǤγÆÀìÌçÎΰ衢IVR¡¢Êü¼ÍÀþ¼£ÎŤˤĤ¤¤Æ¡¢³ÆÎΰè¤òÀìÌç¤È¤¹¤ë»ØƳ°å¤Î¤â¤È¤ÇÎ×¾²¼Â½¬¤ò¹Ô¤¤¤Þ¤¹¡£ÁªÂò¼Â½¬¤Ç¤Ï¡¢³ØÀ¸¤Î´õ˾¤¹¤ëÎΰè¤òÃæ¿´¤Ë»ØƳ°å¤Î¤â¤È¤Ç¼Â½¬¤ò¹Ô¤¤¤½¤ÎÀ®²Ì¤ò³ØÀ¸¤¬È¯É½¤·¤Þ¤¹¡£
¡¡³Ø½Ñ¾ðÊ󥻥󥿡¼¤Î¿Þ½ñ´ÛÆâ¤ËËܳØÉí°É±¡¤ÎPACS¤ÈÏ¢·È¤µ¤»¡¢¸Ä¿Í¾ðÊó¤ò¾Ãµî¤·¤¿¾õÂ֤DzèÁü¤ò±ÜÍ÷¤·±é½¬¤Ç¤­¤ëüËö¤ò8ÂæÀßÃÖ¤·¡¢³ØÀ¸¤Î¤¿¤á¤Î²èÁü¿ÇÃǼ«¸Ê³Ø½¬´Ä¶­¤ò¹½ÃÛ¤·¤Æ¤ª¤ê¤Þ¤¹¡£
Âç³Ø±¡¶µ°é¡¦¸¦µæ¤Ë¤Ä¤¤¤Æ
¡¡Êü¼ÍÀþ°å³Ø¤Ï²èÁü¿ÇÃÇÉôÌç¤ÈÊü¼ÍÀþ¼£ÎÅÉôÌç¤È¤«¤é¹½À®¤µ¤ì¤Þ¤¹¡£²èÁü¿ÇÃǤÏÀèü²Ê³Øµ»½Ñ¤¬½¸·ë¤·¤¿¿ÊÊâ¤Î·ã¤·¤¤Îΰè¤Ç¤¢¤ë¤ÈƱ»þ¤Ë¡¢²èÁü¿ÇÃǤʤ¯¤·¤Æ¸½Âå°åÎŤÏÀ®Î©¤·¤Ê¤¤¤Û¤É¤Ë³Æ²ÊÎ×¾²°å¤«¤é¤Î°Í¸Å٤Ϲâ¤Þ¤Ã¤Æ¤¤¤Þ¤¹¡£Êü¼ÍÀþ¼£ÎŤϴ⼣ÎŤιâÀºÅÙ²½¤¬¿Ê¤ß¡¢¤Þ¤¿¡¢´µ¼Ô¤µ¤ó¤ÎÀ¸³è¤Î¼Á¤òÊݾڤ¹¤ë´ÑÅÀ¤«¤é¡¢µÞ®¤Ë½ÅÍ×À­¤¬ÁýÂ礷¤Æ¤¤¤Þ¤¹¡£
¡¡²èÁü¿ÇÃÇÉôÌç¤Ç¤Ï¡¢MRI¡¢2´Éµå¥Þ¥ë¥Á¥¹¥é¥¤¥¹CT¡¢Ä¶²»Çȸ¡ºº¡¢IVR¡¢³Ë°å³Ø¸¡ºº¡¢¤ª¤è¤Ó²èÁü¿ÇÃǤˤª¤±¤ëIT ´Ä¶­¤Ë´Ø¤¹¤ëÎ×¾²¸¦µæ¤¬¹Ô¤ï¤ì¤Æ¤¤¤Þ¤¹¡£Êü¼ÍÀþ¼£ÎÅÉôÌç¤Ç¤Ï¡¢Æ¬ðôÉô¡¢Æý˼¡¢ÇÙ¡¢¿©Æ»¡¢ÈçÇ¢´ï¡¢½÷À­À¸¿£´ï¤Ê¤É¤Î°­À­¼ðáç¤ËÂФ¹¤ë½¸³ØŪ¼£ÎÅ¡¢¤ª¤è¤Ó¹Ã¾õÁ£¼ðáç¡¢¥Ð¥»¥É¥¦É¡¢Å¾°ÜÀ­¹ü¼ðáç¡¢°­À­¥ê¥ó¥Ñ¼ð¤Ê¤É¤ËÂФ¹¤ëÆâ¾È¼ÍÎÅË¡¤Ë´Ø¤¹¤ëÎ×¾²¸¦µæ¤¬¹Ô¤ï¤ì¤Æ¤¤¤Þ¤¹¡£
¹ÖºÂ(¸¦µæ¼¼)¤«¤é¤Î¥á¥Ã¥»¡¼¥¸

¡¡Êü¼ÍÀþ°å³Ø¹ÖºÂ¤ÏCT¤äMRI¤Ê¤É¤Î¿ÇÃǤò¹Ô¤¦²èÁü¿ÇÃǤȰ­À­¼ðáç¤Î¼£ÎŤò¹Ô¤¦Êü¼ÍÀþ¼£ÎŤËʬ¤«¤ì¤Æ¶µ°é¡¦¿ÇÎÅ¡¦¸¦µæ¤ò¹Ô¤Ã¤Æ¤¤¤Þ¤¹¡£²èÁü¿ÇÃǤϹ¹¤ËÃæ¿õ¿À·Ð¡¢Æ¬ðôÉô¡¢¶»Éô¡¦¿´·ì´É¡¢¾Ã²½´ï¡¢ÈçÇ¢´ï¡¦À¸¿£´ï¡¦ÆýÁ£¡¢¹üÆðÉô¡¢³Ë°å³Ø¿ÇÃÇ¡¢Ä¶²»ÇÈ¿ÇÃÇ¡¢IVR¤Ëʬ¤«¤ì¡¢Êü¼ÍÀþ¼£ÎŤϡ¢¥ê¥Ë¥¢¥Ã¥¯ÁõÃ֤ˤè¤ë³°Éô¾È¼Í¡¢¹âÀþÎÌΨ¾®Àþ¸»¼£Îšʻҵܴ⡢¿©Æ»´â¡Ë¡¢Ì©Éõ¾®Àþ¸»¼£Îšʸý¹Ð¡¦°öƬ´â¡¢Á°Î©Á£´â¡Ë¡¢¥è¡¼¥ÉÆâÉþÎÅË¡¡Ê¥Ð¥»¥É¥¦É¡¢¹Ã¾õÁ£´â¡Ë¡¢áÖÄË´Ëϼ£ÎŤËʬ¤«¤ì¤Þ¤¹¡£Èó¾ï¤Ë¹­¤¤ÈϰϤòºÙʬ²½¤¹¤ë¤³¤È¤Ë¤è¤ê¡¢ÀìÌçÀ­¤Î¹â¤¤¶µ°é¡¦¿ÇÎÅ¡¦¸¦µæ¤ò¹Ô¤Ã¤Æ¤¤¤Þ¤¹¡£

¢¥ ¤³¤Î¥Ú¡¼¥¸¤Î¥È¥Ã¥×¤Ø
¶µ°éôÅö
¹ÖµÁ²ÊÌÜ̾¾Î¤ÈÂоݳØǯ

Î×¾²´ðÁðå³Ø I¡¡Êü¼ÍÀþ´ðÁðå³Ø¡Ê3ǯÀ¸¡Ë
Î×¾²°å³Ø­µ¡¡²èÁü¿ÇÃdzءÊ3ǯÀ¸¡Ë
Î×¾²°å³Ø­¶¡Ê¿·¡Ë²èÁü¿ÇÃdzءʽ¸¹ç¡Ë¡Ê4ǯÀ¸¡Ë
Î×¾²°å³ØII (¿·) ¼ðáç³Ø¡Ê4ǯÀ¸¡Ë

¼Â½¬²ÊÌÜ̾¾Î¤ÈÂоݳØǯ

´ðËÜŪÎ×¾²µ»Ç½¼Â½¬¡¡Êü¼ÍÀþ¿ÇÎŤδðÁáÊ4ǯÀ¸¡Ë
Î×¾²°å³Ø­¶¡Ê¿·¡ËÎ×¾²¼Â½¬¡¡Êü¼ÍÀþ°å³Ø¡¡¡Ê4¡¢5ǯÀ¸¡Ë
ÁªÂò¼Â½¬¡¡Êü¼ÍÀþ°å³Ø¡¡¡Ê5¡¢6ǯÀ¸¡Ë

¢¥ ¤³¤Î¥Ú¡¼¥¸¤Î¥È¥Ã¥×¤Ø
Âç³Ø±¡Ã´Åö²ÊÌÜ̾¾Î
Âç³Ø±¡¥¬¥¤¥É¼ø¶ÈºÙÌÜ¡¡¡¡Êü¼ÍÀþ°å³Ø¡Ê26¥Ú¡¼¥¸¡Ë¤ò¤´»²¾È¤¯¤À¤µ¤¤
¢¥ ¤³¤Î¥Ú¡¼¥¸¤Î¥È¥Ã¥×¤Ø
¼ç¤Ê¸¦µæ¥Æ¡¼¥Þ
1. ¡ÚÃæ¿õ¿À·Ð¡Û
  • ÄǹüÆ°Ì®²òÎ¥¤Î²èÁü½ê¸«¤Î¸¡Æ¤
  • MRI¤Ë¤ª¤±¤ëFabryɤÎËö¾¿¿À·Ð½ê¸«¤Î¸¡Æ¤
  • MRI¤Ë¤ª¤±¤ë»ë¿À·Ð¾ä¤Î²èÁü½ê¸«¤Î¸¡Æ¤
  • »ë¿À·Ð±ê¤Ë¤ª¤±¤ëMRI¤ÎÍ­ÍÑÀ­¤Î¸¡Æ¤
2. ¡ÚƬðôÉô¡Û
  • ƬðôÉô٨ʿ¾åÈé´â¤ËÂФ¹¤ëðôÉô³ÔÀ¶½Ñ¤Î½Ñ¼°É¸½à²½¤Ë¤ª¤±¤ë²èÁü¿ÇÃǤÎÌò³ä¤Ë´Ø¤¹¤ë¸¦µæ
  • IgG4´ØÏ¢¼À´µ¤ÎƬðôÉô¡¦Æ¬ÉôÎΰè¤Î²èÁü¿ÇÃǤθ¡Æ¤
  • Ã漪¿¿¼î¼ð¤Î¿ÊŸ¡¦Í½¸å¿äÄê¤Ë´Ø¤¹¤ë²èÁü¸¦µæ
  • ¾å³Üƶ´â¤ËÂФ¹¤ëĶÁªÂòŪưÃí²½³ØÎÅË¡Ê»ÍÑÊü¼ÍÀþ¼£ÎŸå¤Î²èÁü½ê¸«¤Ë´Ø¤¹¤ë¸¡Æ¤
3. ¡Ú¿´Âç·ì´É¡Û
  • ¿´Â¡CT¤Ë¤ª¤±¤ëº¸¿´¼ªÆ⤱Ʒç»Áü¤Ë´Ø¤¹¤ë¸¡Æ¤
  • ´¶À÷À­¿´ÆâËì±ê½ÑÁ°É¾²Á¤Ë¤ª¤±¤ë¿´Â¡CT¤ÎÍ­ÍÑÀ­¤Î¸¡Æ¤
  • ¿´¶Ú¾É¤Î´ÕÊ̤ˤª¤±¤ë¿´¶ÚT1ÃÍ¡¢T2ÃÍ¡¢ECV¤ÎÍ­ÍÑÀ­¤Î¸¡Æ¤
4. ¡Ú¸ÆµÛ´ï¡Û
  • ÇÙ´â¤Î·Ð»þŪÊѲ½¤ÈÇØ·Ê°ø»Ò¤Ë¤è¤ëͽ¸åͽ¬¤Ë¤Ä¤¤¤Æ¤Î¸¡Æ¤
  • Æþ±¡»þCOVID-19¥¹¥¯¥ê¡¼¥Ë¥ó¥°¶»ÉôCT¤ÎÍ­ÍÑÀ­¤Îɾ²Á
5. ¡Ú´ÎÃÀ繡¦¾Ã²½´É¡Û
  • EOB-MRI¤òÍѤ¤¤¿Å¾°ÜÀ­´Î¼ðáç¤Îͽ¸åɾ²Á
  • ´Î¡dynamic¤±ÆMRI¤Ë¤ª¤±¤ë¼«Í³¸ÆµÛ²¼»£Áü¤ÎÍ­ÍÑÀ­¤Î¸¡Æ¤
  • ÃÀǹ´â¤ÈÃÀǹ¥Ý¥ê¡¼¥×¤Î´ÕÊ̤ˤª¤±¤ëÈó¤±ÆMRI¤ÎÍ­ÍÑÀ­¤Î¸¡Æ¤
6. ¡ÚÈçÇ¢´ïÀ¸¿£´ï¡¦Æý˼¡Û
  • »ÒµÜÆâËì¼ðáî¤ÎMRI½ê¸«¤Î¸¡Æ¤
  • ÍñÁãÞù±ÕÀ­¼ðáç¤Î¿Ãʳ¬È¯¤¬¤ó¤È²èÁü½ê¸«¤Î¸¦µæ
  • ÆýÁ£MRI¤Ë¤ª¤±¤ëÇØ·ÊÆýÁ£¤ÎÁý¶¯¸ú²Ì¤Ë´Ø¤¹¤ë¸¦µæ
  • MRI¤Ë¤è¤ëÆýÁ£¾É¤Îͽ¸«°ø»Ò¤Ë´Ø¤¹¤ë¸¡Æ¤
7. ¡Ú¹üÆðÉô¡Û
  • Dual-Energy CT¤òÍѤ¤¤¿´ØÀá¥ê¥¦¥Þ¥Á¤ÎÄêÎ̲½¤Ë¤Ä¤¤¤Æ¤Î¸¡Æ¤
  • ¹üÆðÉôÎΰè¤Ø¤Îdual energy CTÍøÍѤ˴ؤ¹¤ë¸¦µæ
  • ÀÔÄÇMRI¤Ë¤ª¤±¤ë¹üÁÆò¢À­°µÇ÷¹üÀÞ¤Îͽ¬°ø»Ò¤Î¸¡Æ¤
  • ultrashort TE MRI¤Ë¤è¤ë秡¦¿ÙÂÓ¤ÎÄêÎÌɾ²Á
8. ¡ÚĶ²»ÇÈ¿ÇÃÇ¡Û
  • ÆýÁ£Ä¶²»ÇȲèÁü¤Ë´Ø¤¹¤ë¿Í¹©ÃÎǽÍѥǡ¼¥¿¥Ù¡¼¥¹À°È÷¤Î¸¦µæ
  • Ķ²»ÇÈÃÇÁظ¡ºººÇ¿·µ»½Ñ¤ÎÎ×¾²±þÍѤ˴ؤ¹¤ë¸¦µæ
9. ¡Ú³Ë°å³Ø¡Û
  • ¹Ã¾õÁ£Ê¬²½´â¤ËÂФ¹¤ëI-131 adjuvant¼£ÎÅͽ¸å°ø»Ò¤Î¸¡Æ¤
  • µîÀªÄñ¹³À­Á°Î©Á£´â¹üž°Ü¤ËÂФ¹¤ëRa-223¸ú²ÌȽÄê¤Î¼£ÎÅÀ®ÀÓ¡¢¼£ÎŸú²Ì¤È´ØÏ¢¤¹¤ëÇØ·Ê°ø»Ò¤Î¸¡Æ¤
  • Lymphatic malformations¤Ë¤ª¤±¤ë¥ê¥ó¥Ñ´É¥·¥ó¥Á¥°¥é¥Õ¥£¤Î½ê¸«Ê¬Îà
10. ¡Ú¥¤¥ó¥¿¡¼¥Ù¥ó¥·¥ç¥Ê¥ë¥é¥¸¥ª¥í¥¸¡¼¡Û
  • ²èÁü¥¬¥¤¥É²¼¤ÎÀü»É¡¢À¸¸¡¡¢Ä㿯½±À­¼£ÎŤؤαþÍѤ˴ؤ¹¤ë¸¦µæ
  • ¾å³Üƶ´â¤ËÂФ¹¤ë¥·¥¹¥×¥é¥Á¥óÆ°ÃíÊ»ÍÑÊü¼ÍÀþ¼£ÎÅ
  • ÂçÎÌ´ÎÀÚ½ü½ÑÁ°¤ÎÌçÌ®¡¢´ÎÀÅ̮Ʊ»þºÉÀò½Ñ¤ÎÍ­¸úÀ­¡¢°ÂÁ´À­¤Î¸¡Æ¤
  • ·ì´É¼ð¡¦·ì´É´ñ·Á¤ËÂФ¹¤ë·ì´ÉÆâ¼£ÎŤÎÍ­¸úÀ­¡¢°ÂÁ´À­¤ò³Îǧ¤¹¤ë¸¦µæ
  • Automated tumor-feeder detection software¤Ë¤è¤ëÃÀǹư̮¤Î¸¡½Ð¡¢·ëIJ·Æ¼¼½Ð·ì¤ÎÀÕǤ·ì´É¤ÎƱÄê
  • VAIVT¤Ë¤ª¤±¤ë¥Ð¥ë¡¼¥ó³ÈÄ¥»þ¤ÎáÖÄË´ÉÍý¤Ë´Ø¤¹¤ë¸¡Æ¤
  • ¥ê¥ó¥Ñϳ¤ËÂФ¹¤ëIVR¼£ÎŤÎÍ­¸úÀ­¡¢°ÂÁ´À­¤Ë´Ø¤¹¤ë¸¡Æ¤
12. ¡ÚÊü¼ÍÀþ¼£ÎÅ¡Û
  • »ë¿À·Ð¾ä¿ñËì¼ð¤ËÂФ¹¤ë¹âÀºÅÙÊü¼ÍÀþ¼£ÎŤαþÍѤ˴ؤ¹¤ë¸¦µæ
  • Á°Î©Á£´â½Ñ¸å¾È¼Í¤Ë¤ª¤±¤ëIMRT¤Î±þÍѤ˴ؤ¹¤ë¸¦µæ
  • Á°Î©Á£´â¤ËÂФ¹¤ëÄê°Ì¾È¼Í¤ÎºÇŬ²½¤Ë´Ø¤¹¤ë¸¦µæ
  • ƬðôÉô´â¤ËÂФ¹¤ë¹âÀºÅÙÊü¼ÍÀþ¼£ÎŤ˴ؤ¹¤ë¸¦µæ
  • ÄÇÂΞ°Ü¤ËÂФ¹¤ëÄê°Ì¾È¼Í¤ÎÍ­¸úÀ­¤Ë´Ø¤¹¤ë¸¦µæ
 
¢¥ ¤³¤Î¥Ú¡¼¥¸¤Î¥È¥Ã¥×¤Ø
¼ç¤Ê¶ÈÀÓ
  1. Ouchi K, Sakuma T, Nojiri A, Kano R, Higuchi T, Yakabe H, Hasumi J, Suzuki T, Fujioka H, Ogihara A, Yoshimoto S, Igarashi T, Ojiri H, Kawai M, Matsumura Y, Yoshitake M, Kunihara T. Optimal threshold score of aortic valve calcification for identification of significant aortic stenosis on non-electrocardiographic-gated computed tomography. Eur Radiol. 2023;33:1243-1253.
  2. Baba A, Kurokawa R, Kurokawa M, Ota Y, Srinivasan A. Dynamic Contrast-Enhanced MRI Parameters and Normalized ADC Values Could Aid Differentiation of Skull Base Osteomyelitis from Nasopharyngeal Cancer. AJNR Am J Neuroradiol. 2023;44:74-78.
  3. Matsushima S, Omoto S, Shimizu T, Baba A, Ojiri H. Cauda Equina Atrophy in Amyotrophic Lateral Sclerosis on Routine Lumbar Magnetic Resonance Imaging. J Comput Assist Tomogr. 2022;46:991-996.
  4. Shiraishi M, Igarashi T, Hiroaki F, Oe R, Ohki K, Ojiri H. Radiomics based on diffusion-weighted imaging for differentiation between focal-type autoimmune pancreatitis and pancreatic carcinoma. Br J Radiol. 2022;95:20210456.
  5. Nozawa Y, Michimoto K, Ashida H, Baba A, Fukuda T, Ojiri H.¡¡Inferior vena cava diameter on CT angiography predicts mesenteric angiography positive for extravasation in colonic diverticular bleeding. Radiol Med. 2022;127:1412-1419.
  6. Baba A, Kurokawa R, Rawie E, Kurokawa M, Ota Y, Srinivasan A. Normalized Parameters of Dynamic Contrast-Enhanced Perfusion MRI and DWI-ADC for Differentiation between Posttreatment Changes and Recurrence in Head and Neck Cancer. AJNR Am J Neuroradiol. 2022;43:1184-1189.
  7. Fukuda T, Kayama R, Ogiwara S, Yonenaga T, Ojiri H. Comparison of the axillary lymph node between rheumatoid arthritis and psoriatic arthritis with computed tomography. Acta Radiol Open. 2022;11:20584601221112616.
  8. Baba A, Kurokawa R, Fukuda T, Fujioka H, Kurokawa M, Fukasawa N, Sonobe S, Omura K, Matsushima S, Ota Y, Yamauchi H, Shimizu K, Kurata N, Srinivasan A, Ojiri H. Radiological features of human papillomavirus-related multiphenotypic sinonasal carcinoma: systematic review and case series. Neuroradiology. 2022;64:2049-2058.
  9. Relationships between contrast-enhanced computed tomography features of hard palate cancer and pathological depth of invasion. Baba A, Kurokawa R, Kurokawa M, McHugh JB, Hines C, Ota Y, Srinivasan A. Oral Surg Oral Med Oral Pathol Oral Radiol. 2022;134:649-657.
  10. Morikawa K, Misumi S, Igarashi T, Fujimori A, Ogihara A, Akao R, Hasumi J, Watanabe T, Fujii Y, Ojiri H, Mori S. Clinical significance of chest CT for the exclusion of COVID-19 in pre-admission screening: Is it worthwhile using chest CT with reverse-transcription polymerase chain reaction test? Respir Investig. 2022;60:595-603.
  11. Kisaki S, Igarashi T, Ashida H, Furuhashi H, Ojiri H. The Utility of Submucosal Linear Enhancement on Dynamic Computed Tomography for Patients With Internal Hemorrhoids. J Comput Assist Tomogr. 2022;46:688-692.
¢¥ ¤³¤Î¥Ú¡¼¥¸¤Î¥È¥Ã¥×¤Ø
¹ÖºÂ¡Ê¸¦µæ¼¼¡ËÆȼ«¤Î¥Û¡¼¥à¥Ú¡¼¥¸URL
Åìµþ»ü·Ã²ñ°å²ÊÂç³Ø¡¡Êü¼ÍÀþ°å³Ø¹ÖºÂ
https://jikei-radiology.jp/
¢¥ ¤³¤Î¥Ú¡¼¥¸¤Î¥È¥Ã¥×¤Ø